Healthcare [ 11/13 ] | Biotechnology [ 98/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.61 Increased by +54.14% | -1.69 Increased by +63.91% |
| Aug 7, 23 | -1.98 Decreased by -141.46% | -0.21 Decreased by -842.86% |
| May 9, 23 | 1.87 Increased by +196.39% | 0.06 Increased by +3.02 K% |
| Mar 28, 23 | 4.43 Increased by +401.36% | 0.98 Increased by +352.04% |
| Nov 9, 22 | -1.33 Increased by +35.12% | -1.81 Increased by +26.52% |
| Aug 9, 22 | -0.82 Increased by +60.39% | -1.9 Increased by +56.84% |
| May 9, 22 | -1.94 Increased by +9.77% | -1.44 Decreased by -34.72% |
| Feb 28, 22 | -1.47 Decreased by -17.6% | -1.72 Increased by +14.53% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 43.38 M Increased by +224.45% | -16.22 M Increased by +52.98% | Decreased by -37.4% Increased by +85.51% |
| Jun 30, 23 | 9.56 M Decreased by -64.7% | -52.55 M Decreased by -149.8% | Decreased by -549.4% Decreased by -607.56% |
| Mar 31, 23 | 79.73 M Increased by +1.42 K% | 50.75 M Increased by +197.68% | Increased by +63.66% Increased by +106.42% |
| Dec 31, 22 | 160.05 M Increased by +2.66 K% | 117.35 M Increased by +403.5% | Increased by +73.32% Increased by +110.99% |
| Sep 30, 22 | 13.37 M Increased by +448.58% | -34.5 M Increased by +36.21% | Decreased by -258.07% Increased by +88.37% |
| Jun 30, 22 | 27.09 M Increased by +1.25 K% | -21.04 M Increased by +61.46% | Decreased by -77.65% Increased by +97.15% |
| Mar 31, 22 | 5.24 M Increased by +146.54% | -51.96 M Increased by +7.79% | Decreased by -990.83% Increased by +62.6% |
| Dec 31, 21 | 5.79 M Increased by +158.89% | -38.66 M Decreased by -24.31% | Decreased by -667.31% Increased by +51.99% |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.